HR 1376, the Healthy Poultry Assistance and Indemnification Act of 2025, provides compensation to poultry growers and layer facility owners whose operations were prohibited within USDA-designated "control areas" due to animal health restrictions. It directly affects poultry farmers raising birds bred for meat or eggs (like chickens, turkeys, or ducks), excluding doves and pigeons. The bill requires the Secretary to pay compensation equal to the average income from the farm's five most recent flocks multiplied by the number of prohibited flocks, minus any prior state compensation received, with payments due within 60 days of a claim. This mechanism ensures financial support for farmers impacted by USDA-mandated restrictions without requiring judicial review of payment amounts.
Investing in Rural America Act of 2025 This bill allows Farm Credit System (FCS) institutions to make and participate in loans and commitments (and extend other technical and financial assistance) for essential community facility projects as part of the Department of Agriculture's Community Facilities Direct Loan & Grant Program. This program provides funding to develop essential community facilities in rural areas. The FCS financing and technical assistance may be provided in order to make capital available to develop, build, maintain, improve, or provide related equipment or other support for essential community facilities in rural communities (e.g., certain facilities that provide healthcare, community support, public safety, educational, or utility services). Under the bill, the financing provided by an FCS institution may not exceed 15% of the total of all outstanding loans of the institution. Further, an FCS institution must (1) offer at least one non-FCS lending institution an interest in the financing under reasonable terms and conditions acceptable to the borrower, and (2) report the offer to the Farm Credit Administration (FCA). The FCA must submit an annual report to Congress on the activities undertaken by FCS institutions under this bill, including through the partnerships between FCS institutions and other lending institutions. The FCA must post the report on the administration's website.
HRES 230 is a non-binding resolution expressing Congress's sense that the U.S. Congress and administration must urgently collaborate on food and agricultural trade policies. It directly affects U.S. farmers, ranchers, and the $9.6 trillion agricultural sector, which supports millions of jobs and generates significant exports. The resolution calls for concrete actions including securing new market access, enforcing trade agreements, eliminating unjustified trade barriers (like tariffs and nontariff restrictions), and using science-based approaches to strengthen global trade. It emphasizes addressing a 9% decline in 2023 agricultural exports and a projected $37 billion trade deficit, contrasting with historical trade surpluses.
HRES 227 is a non-binding resolution expressing the House of Representatives' support for designating March 18, 2025, as "National Agriculture Day" to honor agriculture's role as a vital U.S. industry. It does not create new laws, allocate funds, or impose requirements on any group. The resolution serves as a symbolic gesture to highlight agriculture's economic impact and contributions to the nation. As a procedural resolution, it has no direct policy effect beyond raising awareness.
The Innovative FEED Act of 2025 establishes a new regulatory category for "zootechnical animal food substances" - additives in animal feed that affect digestive byproducts, reduce foodborne pathogens, or alter an animal's gut microbiome without providing nutrition. These substances would be regulated as food additives (not drugs) under the Federal Food, Drug, and Cosmetic Act, requiring manufacturers to submit specific safety and efficacy data for approval. The bill mandates labeling stating "Not for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals" and allows optional claims about intended effects on animal body function. It explicitly excludes existing drugs, hormones, ionophores, and other substances from this category, ensuring no mandatory use of these additives.
This bill (HR 2199) prevents private health insurance plans from discriminating against patients with end-stage kidney disease (ESRD) who require dialysis. It amends the Social Security Act to prohibit plans from treating dialysis coverage differently than other medical services or applying network restrictions that disproportionately harm ESRD patients. The law clarifies that plans cannot deny or limit benefits for dialysis based on a patient’s diagnosis, while preserving a plan’s right to choose which dialysis providers are in their network. It directly affects ESRD patients and their private health insurance coverage, ensuring dialysis is treated equally with other covered medical services. The bill does not require plans to include specific dialysis providers but stops them from unfairly restricting access to necessary care.
HR 2188 (COST Act) requires two studies to inform federal fleet decisions. The Comptroller General must analyze the costs of replacing gasoline-powered federal vehicles with electric or E85 flex-fuel vehicles, including necessary infrastructure. The Energy Secretary must compare lifecycle greenhouse gas emissions of conventional gasoline, E85 flex-fuel, and electric vehicles using established models. Both studies must be completed within one year of enactment, providing data for future federal vehicle fleet policies without changing existing regulations.
This bill modifies Medicare's physician self-referral rules to improve access for rural communities. It creates a new exemption for "covered rural hospitals" (defined as facilities in rural areas more than 35 miles from another hospital or critical access hospital) from certain restrictions on physicians owning hospitals. The bill also removes a prohibition on expanding existing physician-owned hospitals, allowing such expansions after the law's enactment. These changes directly affect rural hospitals seeking Medicare participation and physicians who own or operate hospitals in underserved areas.
The Air America Act of 2025 authorizes one-time payments of $40,000 to individuals who worked for Air America or its affiliated companies for at least five years during 1950-1976, or to their surviving spouses, children, or dependents. Additional payments of $8,000 per full year beyond five years are allowed. The program is capped at $60 million total funding, with claims required within two years of final regulations. Payments are a single lump sum with no ongoing benefits, and the bill explicitly states it does not create new entitlements beyond this one-time award.
HR 2220, the PARA-EMT Act of 2025, creates a federal grant program to address the shortage of emergency medical technicians (EMTs) and paramedics. It authorizes $50 million annually (2026-2030) for grants to EMS agencies to fund recruitment, training, and retention programs - prioritizing youth, rural areas, and veterans with military EMS training. A separate $20 million annually supports state grants to help veterans transition to civilian EMT roles by covering certification costs and licensing fees. The bill also mandates a federal study on projected EMS workforce needs through 2034 to inform future policy. It directly affects EMS agencies, training programs, and veterans seeking civilian EMT careers.
This bill changes a tax rule for Real Estate Investment Trusts (REITs) that use taxable subsidiaries. It increases the percentage limit for assets held in these subsidiaries from 20% to 25% of a REIT's total assets, directly affecting REIT companies that operate through such subsidiaries. The key provision amends the Internal Revenue Code to restore this higher asset threshold, which had been reduced earlier. The change applies to taxable years starting after December 31, 2025.
This bill prohibits pharmacy benefit managers (PBMs) from receiving payments tied to prescription drug prices or rebates starting January 1, 2027. Instead, PBMs may only charge flat, itemized fees for actual services performed (e.g., claim processing), not based on drug costs or discounts. It directly affects PBMs and health insurance plans by requiring compensation to be decoupled from drug pricing, while allowing rebates to be passed through to lower net drug costs. The law aims to reduce conflicts of interest in PBM operations without changing drug pricing itself.
